Financial Information
We introduce ADBIOTECH’s technology intended to replace vaccines
and antibiotics.
(Unit: KRW in millions)
Sales
Operating profit
Net profit
Income Statements(Unit: KRW in millions)
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating profit | -4,762 | -4,117 | -3,501 |
| Other gains | 7 | 164 | 98 |
| Other losses | 2,946 | 597 | 1,513 |
| Finance costs | 2,693 | 5,324 | 4,147 |
| Finance income | 4,938 | 862 | 5,554 |
| Cost Of Sales | 3,218 | 4,007 | 5,148 |
| Net profit | -5,432 | -8,987 | -3,329 |
| Sales | 10,472 | 11,136 | 12,897 |
(Unit: KRW in millions)
Total Assets
Total liabilities
Total equity
Financial Position(Unit: KRW in millions)
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Total Assets | 28,093 | 23,074 | 48,407 |
| Current Assets | 13,417 | 8,390 | 20,854 |
| Non-current Assets | 14,676 | 14,685 | 27,554 |
| Total equity | 10,847 | 2,975 | 13,540 |
| Capital surplus | 27,257 | 25,557 | 35,617 |
| Share capital | 4,570 | 4,570 | 8,180 |
| Retained earnings | -16,431 | -24,381 | -27,672 |
| Current liabilities | 12,990 | 15,297 | 31,478 |
| Total liabilities | 17,246 | 20,099 | 34,868 |
| Non-Current liabilities | 4,256 | 4,803 | 3,389 |